Antipsychotic Agents - Adverse effects
Research News and Information

Sunday, November 22, 2009

Asenapine.

30 Oct 2009 In August 2009, asenapine (Saphris; Schering-Plough) was approved by the US FDA for the acute treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in ... Read more...

Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms.

30 Oct 2009 CONTEXT: Several studies have indicated that atypical antipsychotics (AAP) induce obsessive-compulsive (OC) symptoms. Research exploring the mechanism of this phenomenon, however, has been extremely limited. Considering the indirect evidence of ... Read more...

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

26 Oct 2009 CONTEXT: Cardiometabolic effects of second-generation antipsychotic medications are concerning but have not been sufficiently studied in pediatric and adolescent patients naive to antipsychotic medication. OBJECTIVE: To study the association of ... Read more...

Latest indexed articles for 'Antipsychotic Agents - Adverse effects'

These are the very latest articles for this heading:

• Asenapine. 30 Oct 2009
• Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. 30 Oct 2009
• Ziprasidone and citalopram use in pregnancy and lactation in a woman with psychotic depression. 30 Oct 2009
• Psychotic woman with painful abdominal distension. Life-threatening psychotropic drug-induced gastrointestinal hypomotility. 30 Oct 2009
• Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents. 26 Oct 2009
• Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. 26 Oct 2009
• Atypical antipsychotics in the elderly: a review of therapeutic trends and clinical outcomes. 29 Sep 2009
• Clinical trials design lessons from the CATIE study. 29 Sep 2009
• The influence of hepatic impairment on the pharmacokinetics of paliperidone. 29 Sep 2009
• Predicting age-specific dosing of antipsychotics. 29 Sep 2009
• [Use of psychotropic medication among individuals with mental retardation] 8 Sep 2009
• [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists] 30 Aug 2009
• The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. 30 Aug 2009
• Asenapine. 30 Aug 2009
• Treatment of bipolar disorders and metabolic syndrome: implications for primary care. 30 Aug 2009
• Fatal pulmonary embolism following antipsychotic treatment and physical restraint. 30 Aug 2009
• Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia. 30 Aug 2009
• Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. 30 Aug 2009
• Body mass index changes and chronic neuroleptic drug treatment for Tourette syndrome. 30 Aug 2009
• Activation induced by high-dose ziprasidone: a case report. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Antipsychotic Agents'

Definition: Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in schizophrenia, senile dementia, transient psychosis following surgery or myocardial infarction, etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Registry Number: 0

Descriptor UI: D014150

Alternative terms: Antipsychotic Agents; Agents, Antipsychotic; Tranquilizing Agents, Major; Agents, Major Tranquilizing; Major Tranquilizing Agents; Tranquillizing Agents, Major; Agents, Major Tranquillizing; Major Tranquillizing Agents; Major Tranquilizers; Tranquilizers, Major; Antipsychotics; Antipsychotic Drugs; Drugs, Antipsychotic; Neuroleptic Drugs; Drugs, Neuroleptic; Neuroleptics; Neuroleptic Agents; Agents, Neuroleptic;

Related Mesh Headings: Dopamine Antagonists;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.696.277.950.040; D27.505.954.427.210.950.040; D27.505.954.427.700.872.331;

Online Note: use ANTIPSYCHOTIC AGENTS to search TRANQUILIZING AGENTS, MAJOR 1975-94; use TRANQUILIZING AGENTS to search NEUROLEPTICS 1969-94

History Note: 95; was TRANQUILIZING AGENTS, MAJOR 1975-94; ANTIPSYCHOTIC AGENTS was see TRANQUILIZING AGENTS, MAJOR 1975-94; NEUROLEPTICS was see TRANQUILIZING AGENTS 1975-78, was see under TRANQUILIZING AGENTS 1969-74

Technical Notes: GEN or unspecified; prefer specific groups or specific drugs; consider also PSYCHOSES /drug ther